1. Europejska Agencja Leków http:/ www.ema.europa.eu

2. Khullar V, Cambronero J, Angulo J, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB). Eur Urol 2013; 63: 283-295.

3. Dutkiewicz S.: Leczenie nietrzymania moczu wysiłkowego u kobiet, Nowa Medycyna, 2002, 4, 117, 27-28.

4. Radziszewski P, Gugała A, Majewski M, Borkowski T, Borkowski A. Pęcherz nadreaktywny. Przewodnik Lekarza 2008; 10(102):1-7.

5. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003; 62(5Suppl 2): 28-37. 6. Abrams P. et al.: The standarisation of terminology of lower urinary tract function: report from the Standarisation Sub-comitee of the International Continence Society, Neurourol. Urodyn., 2002, 21, 167-178.

7. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary symptoms in five countries: results of the EPIC study. Eur Urol 2006; suppl 6:1306-1314.

8. Dutkiewicz S. Łagodny rozrost stercza, w: Dutkiewicz S. red. Choroby stercza (gruczołu krokowego). Wyd. Med. Termedia, Poznań, 2010,(155-223).

9. Oelke M, Baard J, Wijkstra H, et al. Age and bladder obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008; 54:419-426.

10. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am 2011; 95:87-100.

11. Abrams P, Cardozo L, Khoury S, Wein A, (eds). Incontinence 3rd International consultation on Incontinence. 3rd ed. Health Publ LTD. Plymouth, England 2005.

12. Dutkiewicz S.Problem pęcherza nadaktywnego (OAB) i nietrzymania moczu (NM).Praktyka Lekarska 2009; 17/2:12-17.

13. Chapple CR. Muscarinic receptor antagonists In the treatment of overactive bladder. BJU 2000; 3: 33-46.

14. Chapple C, Khullar V, Gabriel Z,et al. The effect of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48(1): 5-26.

15. Chapple C, Khullar V, Gabriel Z, et al. The effect of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54(3): 543-562.

16. Michel MC, Vrydag W. Alpha 1-, alpha 2- and beta-adrenoreceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147 Suppl 2: S88-119.

17. Chapple CR, Kaplan S, Mitcheson HD, et al. Randomised, double-blind, active-controlled phase III study to assess 12-month safety and efficacy of mirabegron, a beta3-adrenoceptor agonist, in overactive bladder (OAB). Eur Urol 2013; 63(2):296-305.

18. Nitti V, Herschorn S, Khullar V, et al. Efficacy of mirabegron in patients with and without prior treatment with antimuscarinic therapy for overactive bladder (OAB): prespecified analysis of three randomized phase III studies. 37th Annual Meeting of the International Urogynecological Association, 4-8 of September 2012, Poster 34, Brisbane, Australia.

19. Nitti V, Herschorn S, Khullar V, et al. Efficacy of the selective beta3-adrenoceptor agonist, mirabegron, in patients with overactive bladder (OAB) who discontinued prior antimuscarinic therapy due to insufficient effect: pooled analysis of three randomized phase III studies. 37th Annual Meeting of the International Urogynecological Association, 4-8 of September 2012, Poster 351, Brisbane, Australia.

20. Khullar V, Cambronero J, Angulo J, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): post hoc analysis of a prospective, randomized, active and placebo-controlled European-Australian Phase III study. 28th Annual European Association of Urology Meeting, 24-28 of Febuary 2012, Poster 684, Paris.